



MASTER TRIAL LIST

DECEMBER 2023

 New or ReOpened Trials
 No Trials Currently Available

JUST IN TIME TRIALS (JIT)

| | | |
|-----------------------------|-------------------------|-------------------------------|
| AML | ANAL | ALL |
| APL | BILIARY | BLADDER-UROTHELIAL |
| BRAIN | BREAST/ GYN | CANCER CONTROL |
| CLL | CML | COLON-RECTAL |
| ESOPHAGEAL - GASTRIC | HEAD & NECK | LYMPHOMA |
| MDS/MPN | MELANOMA | MERKEL |
| MOLECULAR STUDIES | MULTIPLE MYELOMA | NEUROENDOCRINE |
| NSCLC | PANCREATIC | PROSTATE |
| RADIATION TRIALS | RENAL CELL | SMALL CELL LUNG CANCER |

Updated 12.13.23

RADIATION LOCATIONS:

- OSF Glen Oak - OSF main hospital
- OSF Route 91 (attached to Illinois CancerCare)
- Carle Health Greater Peoria)
- Galesburg - Western Illinois Cancer Treatment Center
- SJMC - St Joseph Medical Center



JUST IN TIME (JIT) TRIALS

*Contact Disease Specific Navigator

Multi-Disease Site: Advanced/Metastatic Solid Tumors

EAY191
(Combomatch) - S3

Molecular Analysis for combination Therapy Choice **(SUBSTUDY- S3: A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)**

RAIN-3202

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

ALL

EA9213

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Breast

EAY191
(Combomatch) - N2

Molecular Analysis for combination Therapy Choice **(SUBSTUDY- N2: Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)**

Gynecological

GY026

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Genitourinary - Rare

A031702

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors *(temp closed cohorts - small cell carcinoma/neuroendocrine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU)*

Head & Neck

EA3191

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

EA3211

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

| | |
|--------------------------------|--|
| <u>HN010</u> | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer |
| Liposarcoma | |
| <u>A092107</u> | Temporarily Closed A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma |
| Melanoma | |
| <u>A091903</u> | Temporarily Closed A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma |
| Neuroendocrine | |
| <u>S2104</u> | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |
| Pancreas | |
| <u>A022106</u> | NEW! Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) |
| <u>S2104</u> | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |
| Rectal | |
| <u>EA2201</u> | Temporarily Closed (RT at Glen Oak, UPHM, Galesburg) A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma |



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

DECEMBER 2023

[MENU](#)

AML

Navigator - Heather x3661



MASTER TRIAL LIST

DECEMBER 2023



ANAL

Navigator - Carrie x3621

| | |
|-------------------------------|--|
| <u>EA2176</u> | A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients <i>(Reviewing potentials on Case By Case Basis Due To Drug Shortage)</i> |
| <u>EA2182</u> | (RT at Carle, Galesburg, and Glen Oak) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) |



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

DECEMBER 2023

[MENU](#)

APL

Navigator - Heather x3661

There are no trials available at this time



MASTER TRIAL LIST

DECEMBER 2023



ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

| | |
|---|---|
| <u>A041703</u> | REOPENED! A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease (<i>cohort 2: relapsed/refractory B lineage ALL</i>) |
| <u>EA9213 - JIT Trial</u> | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL) |



ILLINOIS
CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

DECEMBER 2023



[MENU](#)

BILIARY

Navigator - Carrie x3621

No trials available at this time



MASTER TRIAL LIST

DECEMBER 2023

MENU

BLADDER / UROTHELIAL

Navigator - Carrie x3621

ADJUVANT / NEOADJUVANT

[S1806](#)

(RT at Glen Oak, SJMC, Carle and Galesburg) Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

METASTATIC

[A032001](#)

Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

[A032002](#)

Temporarily Closed (RT at Glen Oak) Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

[SGNDV001](#)

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)



MASTER TRIAL LIST

DECEMBER 2023



BRAIN

Navigator - Carrie x3621

| | |
|--------------------------------|---|
| <u>A071702</u> | Temporarily Suspended A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma |
| <u>BN011</u> | (RT credentialing pending) A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma |
| <u>N0577</u> | (RT at Glen Oak, RT 91, and Carle) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |



BREAST

Navigator - Angie x3613

DCIS

No trials at this time

NEO/ADJUVANT TREATMENT

S1706*

Not Actively Screening - Contact Navigator - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (All biomarker subgroups eligible) | *JIT TRIAL - expect 1 week delay to consent pt

Neo/Adjuvant - HER2 Positive

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative

BR007

(RT at Galesburg, Glen Oak, Rt 91, Carle, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

BR009

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

J2J-MC-JZLH / EMBER-4

(Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

S2206

NEW! Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Neo/Adjuvant - Triple Negative

A012103

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

| | |
|---|---|
| <u>S2212 / SCARLET</u> | Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study |
| METASTATIC TREATMENT | |
| <u>EAY191 (Combomatch) - E4</u> | A ComboMATCH Treatment Trial E4 : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors |
| Metastatic - HER2 Positive <i>(no trials at this time)</i> | |
| Metastatic - Hormone Receptor Positive / HER2 Negative | |
| <u>EAY191 (Combomatch) - N2 (JIT)</u> | <i>Molecular Analysis for combination Therapy Choice</i> (SUBSTUDY- N2 : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1) |
| <u>S1703</u> | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer |
| <u>S2007</u> | Not Actively Screening - contact Navigator - A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases |
| Metastatic - Triple Negative <i>(no trials at this time)</i> | |
| SURGERY / RADIATION ONLY | |
| <u>MA.39</u> | Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (RT: Glen Oak and Carle) |
| CANCER CONTROL (Breast only) | |
| <u>A211901</u> | Not Actively Screening - Contact Navigator Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
| <u>A212102</u> | (Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: enrolling non-white males only closed cancer cohorts: thyroid, melanoma, and sarcoma</i>) |
| <u>A222004</u> | Not Actively Screening - Contact Navigator A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia |
| <u>EAQ202</u> | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i>) |

| | |
|---|---|
| <u>S2010</u> | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) |
| <u>S2108CD</u> | (Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy |
| <u>S1912CD</u> | <u>Not Actively Screening - Contact Navigator</u> A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) <i>(spouse participation no longer required)</i> |
| <u>S2013</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) |
| <u>URCC 16070</u> | Treatment of Refractory Nausea- for breast cancer patients. |
| <u>URCC-18007</u> | Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i> |
| <u>URCC 19185</u> | (Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) |
| <u>URCC 21038</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting |
| <u>WF-1901</u> | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) |
| GYNECOLOGICAL | |
| Navigator - Angie x3613 | |
| <u>NRG - GY023</u> | Temporarily Closed A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
| <u>EAY191 (ComboMATCH) - A3</u> | NEW! Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial |
| <u>EAY191 (ComboMATCH) - N4</u> | <i>Molecular Analysis for combination Therapy Choice</i> (SUBSTUDY- N4 : A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers) |



CANCER CONTROL

MULTI-DISEASE SITES

| | |
|-----------------------------------|--|
| <u>A211901</u> | <u>Not Actively Screening - Contact Navigator</u> Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
| <u>A212102</u> | (Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: enrolling non-white males only closed cancer cohorts: thyroid, melanoma, and sarcoma</i>) |
| <u>A222004</u> | <u>Not Actively Screening - Contact Navigator</u> A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia |
| <u>EAQ202</u> | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i>) |
| <u>S1912CD</u> | <u>Not Actively Screening - Contact Navigator</u> A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (<i>spouse participation no longer required</i>) |
| <u>S2013</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) |
| <u>S2108CD</u> | (Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy |
| <u>URCC-18007</u> | Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i> |
| <u>URCC 19185</u> | (Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) |
| <u>URCC 21038</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting |
| <u>URCC 22063</u> | NEW! Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia |
| <u>WF-1901</u> | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) |

BREAST

| | |
|--|---|
| <u>S2010</u> | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) |
| <u>URCC 16070</u> | Treatment of Refractory Nausea- for breast cancer patients. |
| COLORECTAL | |
| <u>WF-1806</u> | (M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer |
| LUNG | |
| <u>JOVIALITY 23289</u> | Temporarily Closed (Peoria, Bloomington, Canton, Galesburg, Pekin, Washington) Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare |
| LYMPHOMA | |
| <u>EAQ211</u> | Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma |
| REGISTRY | |
| | Navigator - Heather 243-3661 |
| <u>Connect MM</u> | Connect MM: The Multiple Myeloma Disease Registry (<i>new cohort</i> : relapsed/refractory MM to 1st line, initiated / planning 2nd line tx) |
| <u>Connect Myeloid</u> | The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. (<i>enrolling cohorts</i> : low risk MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable) |
| <u>NHLBI-MDS</u> | Temporarily Closed (Peoria, Bloomington and Galesburg only) -The National Myelodysplastic Syndromes (MDS) Study |



MASTER TRIAL LIST

DECEMBER 2023



CLL

Navigator - Heather x3661

no trials at this time

1st Line

2nd Line, 3rd Line, etc.

MASTER TRIAL LIST

DECEMBER 2023



CML

Navigator - Heather x3661

No trials currently available



MASTER TRIAL LIST

DECEMBER 2023



COLON / RECTAL

Navigator - Carrie x3621

Adjuvant

| | |
|------------------------------|--|
| A022004 | Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer |
| C-14 | (Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (CORRECT-MRD II) |
| EA2201 - JIT | Temporarily Closed (RT at Glen Oak, Carle, Galesburg) A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma |
| GI005 | Temporarily Closed Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA) |
| GI008 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |

Metastatic

| | |
|-----------------------|--|
| S2107 | Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer |
|-----------------------|--|

CANCER CONTROL (Colorectal only)

| | |
|-------------------------|---|
| A211901 | <u>Not Actively Screening - Contact Navigator</u> Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
|-------------------------|---|

| | |
|--------------------------|--|
| <u>A212102</u> | Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: <u>enrolling non-white males only</u> closed cancer cohorts: thyroid, melanoma, and sarcoma</i>) |
| <u>A222004</u> | <u>Not Actively Screening - Contact Navigator</u> A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia |
| <u>EAQ202</u> | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i>) |
| <u>S1912CD</u> | <u>Not Actively Screening - Contact Navigator</u> A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (<i>spouse participation no longer required</i>) |
| <u>S2013</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) |
| <u>S2108CD</u> | (Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy |
| <u>URCC-18007</u> | Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i> |
| <u>URCC 19185</u> | (Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) |

| | |
|-----------------------------------|--|
| <u>URCC 21038</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting |
| <u>URCC 22063</u> | NEW! Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia |
| <u>WF-1901</u> | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) |
| <u>WF-1806</u> | (M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer |

MASTER TRIAL LIST

DECEMBER 2023

MENU

ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

| | |
|--|---|
| <p><u>A022102</u></p> | <p>Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma</p> |
| <p><u>EAY191 (Combomatch) - E4</u></p> | <p>A ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors</p> |
| <p><u>EA2212</u></p> | <p>A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer</p> |

HEAD & NECK

Navigator - Ashton x3611

| | |
|---|--|
| <u>EA3161</u> | (RT at Glen Oak, Carle, Galesburg) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC |
| <u>EA3191 - JIT</u> | A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features |
| <u>EA3211 - JIT</u> | Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma |
| <u>EAY191 (Combomatch) - E4</u> | A ComboMATCH Treatment Trial E4 : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors |
| <u>HN005</u> | Temporarily Closed (RT at Galesburg, Glen Oak; Carle) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer |
| <u>HN009</u> | (RT at Carle and SJMC) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| <u>HN010 - JIT Trial</u> | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer |

S2101

Temporarily Closed | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



Navigator - Heather x3661

LYMPHOMA

HL

No HL trials at this time

NHL

| | |
|------------------------------|---|
| <p><u>A052101</u></p> | <p>A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma</p> |
| <p><u>S1918</u></p> | <p>A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements</p> |



MASTER TRIAL LIST

DECEMBER 2023

MENU

MDS/MPN

Navigator - Heather x3661

| | |
|--|--|
| <u>Connect Myeloid</u> | The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. (<i>enrolling cohorts</i> : newly diagnosed low risk MDS, Treated low risk-MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable) |
| <u>NHLBI-MDS</u> | Temporarily Closed (Peoria, Bloomington and Galesburg only) -The National Myelodysplastic Syndromes (MDS) Study |



MASTER TRIAL LIST

DECEMBER 2023



MELANOMA

Navigator - Carrie x3621

| | |
|--|--|
| <u>A091903 - JIT Trial</u> | Temporarily Closed A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma |
| <u>S2101</u> | Temporarily Closed Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |



MASTER TRIAL LIST

DECEMBER 2023

MENU

MERKEL

Navigator - Carrie x3621

| | |
|--------------------------------------|---|
| <p><u>EA6174</u></p> | <p>Temporarily Closed (RT at Glen Oak, Carle, Galesburg) A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma</p> |
|--------------------------------------|---|



MASTER TRIAL LIST

DECEMBER 2023



MOLECULAR STUDIES

*Contact Disease Specific Navigator

| | |
|---|--|
| <u>A151804</u> | Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events |
| <u>S1823</u> | A Study of miRNA 371 in Patients With Germ Cell Tumor <i>(closed to high risk pts or pts on chemo for testicular cancer)</i> |
| <u>TP-CA-003 (Sculptor)</u> | (Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS) |

MULTIPLE MYELOMA

Navigator - Heather x3661

| | |
|--|--|
| <p><u>Connect MM</u></p> | <p>Connect MM: The Multiple Myeloma Disease Registry (<i>new cohort</i> : <i>relapsed/refractory MM to 1st line, initiated / planning 2nd line tx</i>)</p> |
| <p><u>EAA173</u></p> | <p>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)</p> |
| <p><u>S1803</u></p> | <p>REOPENED! Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)</p> |
| <p><u>S2209</u></p> | <p>A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance</p> |

MASTER TRIAL LIST

DECEMBER 2023

MENU

NEUROENDOCRINE

Navigator - Carrie x3621

| | |
|--|--|
| <u>A021602</u> | Temporarily Closed Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Prior Therapy (CABINET) |
| <u>A021804</u> | A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma |
| <u>S2104 - JIT Trial</u> | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |

NSCLC

Navigator - Ashton x3611

ADJUVANT / NEOADJUVANT

| | |
|-------------------------|--|
| A081801 | Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx.</i>) |
| A151216 | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). |
| EA5181 | Closing 11.20.23 (RT at Glen Oak, Rt 91, Carle, Galesburg, SJMC) Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC |
| LU008 | (RT at Carle, SJMC) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer |
| S1914 | (RT at Glen Oak, Carle, Galesburg, SJMC) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |

METASTATIC - 1st Line

| | |
|---|--|
| EA5163 | Not Actively Screening - Contact Navigator A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis (<i>Reviewing on Case By Case Basis Due To Drug Shortage</i>) |
| EA5182 | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
| GS-US-626-6216 (STAR-121) | (Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations |
| MK 7684A-003 | (Peoria only) A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer |

METASTATIC - 2nd/3rd Line

| | |
|--|--|
| D533BC00001 (LATIFY) | (Peoria only) A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY |
| EA5162 | Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR |
| EAY191 (Combomatch) - E4 | A ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors |

| | |
|------------------------------------|---|
| <u>LUNGMAP</u> | A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (SUB-STUDIES: <u>S1900E</u> - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer) ; <u>S1900G</u> - A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer |
| <u>S2302 (Pragmatica)</u> | A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Pragmatica-Lung) |
| CANCER CONTROL (NSCLC Only) | |
| <u>A211901</u> | Not Actively Screening - Contact Navigator Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
| <u>A212102</u> | (Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash) Blinded Reference Set for Multicancer Early Detection Blood Tests (<i>healthy cohort: enrolling non-white males only</i> <i>closed cancer cohorts: thyroid, melanoma, and sarcoma</i>) |
| <u>A222004</u> | Not Actively Screening - Contact Navigator A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia |
| <u>EAQ202</u> | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i>) |
| <u>JOVIALITY 23289</u> | Temporarily Closed (Peoria, Bloomington, Canton, Galesburg, Pekin, Washington) Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare |
| <u>S2108CD</u> | (Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin) A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy |
| <u>S1912CD</u> | Not Actively Screening - Contact Navigator A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (<i>spouse participation no longer required</i>) |
| <u>S2013</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) |
| <u>URCC-18007</u> | Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i> |
| <u>URCC 19185</u> | (Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) |
| <u>URCC 21038</u> | (Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting |
| <u>URCC 22063</u> | NEW! Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia |
| <u>WF-1901</u> | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) |



MASTER TRIAL LIST

DECEMBER 2023



PANCREATIC

Navigator - Carrie x3621

| | |
|---|--|
| <u>A022106 - JIT</u> | NEW! Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) |
| <u>EA2192</u> | A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO) |
| <u>EAY191 (ComboMATCH) - A3</u> | NEW! Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial |
| <u>EAY191 (Combomatch) - E4</u> | A ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors |
| <u>S2001</u> | Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations |
| <u>S2104 - JIT Trial</u> | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |

MASTER TRIAL LIST

DECEMBER 2023

MENU

PROSTATE

Navigator - Carrie x3621

ADJUVANT

| | |
|------------------------------|--|
| <u>GU008</u> | (RT at Glen Oak, Galesburg, Carle) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i> |
| <u>GU009</u> | (RT at Glen Oak, Galesburg, Carle, Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) |
| <u>GU010</u> | (RT at Carle) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) |

METASTATIC

| | |
|---|---|
| <u>A032101</u> | A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM |
| <u>EAY191 (Combomatch) - E4</u> | A ComboMATCH Treatment Trial E4 : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors |
| <u>GU011</u> | (RT at Glen Oak and Carle) A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) |

S1802

(RT at Glen Oak, SJMC & Carle) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

MASTER TRIAL LIST

DECEMBER 2023

MENU

RENAL CELL

Navigator - Carrie x3621

| | |
|--------------------------------|---|
| <u>A031704</u> | PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE) |
| <u>EA8211</u> | (RT at Rt 91, Glen Oak) Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR) |
| <u>S2200</u> | A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2) |

RADIATION TRIALS

Navigator - Jessica x3615

| ANAL | |
|----------------------------------|---|
| <u>EA2182</u> | (Carle, Galesburg, Glen Oak) A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) |
| BLADDER | |
| <u>A032002</u> | Temporarily Closed (RT at Glen Oak) Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART) |
| <u>S1806</u> | (Glen Oak, SJMC, Carle and Galesburg) Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer |
| BRAIN | |
| <u>N0577</u> | (Glen Oak, RT 91, and Carle) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |
| BRAIN METS | |
| <u>BN012</u> | (RT at Carle) A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases |
| <u>CCTG CE.7</u> | (Glen Oak, Carle) - A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases |
| <u>WF-2201</u> | (Glen Oak; Pending at Rt 91) - Hypofractionated Radiotherapy vs Single Fraction Radiosurgery For Brain Metastasis Patients On Immunotherapy (HYPOGRYPHE) |
| BREAST | |
| <u>BR007</u> | (Galesburg, Glen Oak, Rt 91, Carle, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer |

| | |
|-------------------------------------|---|
| <u>MA.39</u> | (Glen Oak) Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer |
| HEAD & NECK | |
| <u>EA3161</u> | (Glen Oak, Carle, Galesburg) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC |
| <u>EA3211 - JIT</u> | Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma |
| <u>HN005</u> | Temporarily Closed (Galesburg, Glen Oak; Carle) A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer |
| <u>HN009</u> | (RT at Carle and SJMC) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| MERKEL CELL | |
| <u>EA6174</u> | Temporarily Closed (Glen Oak, Carle and Galesburg) A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma |
| NSCLC | |
| <u>EA5181</u> | Closing 11.20.23 (Carle, Glen Oak, Rt 91, and Galesburg) Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC |
| <u>LU008</u> | (RT at Carle, SJMC) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer |
| <u>S1914</u> | (Glen Oak, Carle, Galesburg, SJMC) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |
| PROSTATE | |

| | |
|-------------------------|--|
| <u>GU008</u> | (RT at Glen Oak, Galesburg, Carle) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i> |
| <u>GU009</u> | (RT at Glen Oak, Galesburg, Carle, Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) |
| <u>GU010</u> | (RT at Carle) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) |
| <u>GU011</u> | (RT at Glen Oak & Carle) A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) |
| <u>S1802</u> | (Glen Oak, SJMC & Carle) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer |
| RENAL | |
| <u>EA8211</u> | (RT at Rt 91, Glen Oak) Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR) |
| SCLC | |
| <u>NRG CC009</u> | (Glen Oak, Carle) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer |
| <u>S1827</u> | (Glen Oak, Galesburg, SJMC, Carle) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer |

SMALL CELL LUNG CANCER

Navigator - Ashton x3611

| | |
|--|---|
| <p><u>NRG CC009</u></p> | <p>(RT at Glen Oak, Carle) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p> |
| <p><u>GO43104</u></p> | <p>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Followiing First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab</p> |
| <p><u>S1827</u></p> | <p>(RT at Glen Oak, Galesburg, SJMC, Carle) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p> |
| <p><u>TP-CA-003 (Sculptor)</u></p> | <p>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p> |